The outbreak's footprint is still growing — and this week WHO is rolling out a new test and launching a treatment trial while the fire's still burning. Here's how we got here. DRC's Bundibugyo Ebola outbreak has stayed active in the northeast, with sustained transmission and security constraints around response sites. A July 15 attack on the Nyakunde Treatment Centre pushed MONUSCO to deploy a nearby mobile base to protect hospitals and patients, and peacekeepers later reported that calm had returned around Marabo. Officials and partners have been trying to keep surveillance, treatment, and protection running all at once. This is Ebola Watch. A brand-new diagnostic and a treatment trial both arrived this week while the fire's still spreading. So today, I want the honest answer: what do you actually do in the gap? Let's get into it. If this story matters to you — DRC Bundibugyo Ebola outbreak — hit follow. We'll be back on it soon. ReliefWeb writes:
Transmission of Bundibugyo virus disease (BVD) remained intense in the Democratic Republic of the Congo during the reporting week, with continued detection of new confirmed cases and deaths across multiple affected areas, alongside further expansion of the outbreak's geographic footprint. The epidemiological situation outside the Democratic Republic of the Congo remained stable, with no new cases or evidence of secondary transmission reported in Uganda or France.
Since Situation Report number nine on July 12th, there've been another 460 confirmed cases and 248 confirmed deaths. Confirmed, not suspected. That distinction matters, and ReliefWeb makes it clear. That's 460 more cases, and the footprint's wider again. What does the map look like now? There are five new health zones: Pawa, Boma Mangbetu, and Isiro in Haut-Uélé, plus Mahagi and Adja in Ituri. That takes the total from 42 to 47 affected zones. Mahagi and Adja — that's Ituri, right up against the Ugandan border. So for the traveler asking the honest question: is this getting closer to crossing the border? As of this update, there are no new cases and no secondary spread in Uganda or France. Things are deteriorating inside DRC, while the situation across the borders has held so far. I'd keep those facts separate. The other number that jumped out at me: case fatality rose from 36.6 to 39.9 percent. That makes it sound like the virus itself got worse. Careful there. The report attributes that rise to late detection and deaths outside treatment facilities — people dying before they ever reach care. It doesn't say the pathogen itself has become more lethal. Which is its own kind of grim — the fatal gap is at the clinic's front door. And remember, Bundibugyo is a different Ebola virus species, so right now there's no licensed shot or antiviral cleared for it. Michael van den Heuvel, writing in Medscape:
The largest recorded outbreak of Ebola disease due to Bundibugyo virus (BVD) continues to expand in the Democratic Republic of the Congo (DRC), prompting international efforts to improve diagnosis and treatment. As case counts continue to rise, the World Health Organization (WHO) has introduced a newly validated diagnostic test and launched an international clinical trial to evaluate potential treatments.
So here's the thing that jumped out at me — WHO just introduced a newly validated, Bundibugyo-specific test. Which raises the obvious question: what were field teams using to confirm those 2,011 cases before today? A newly validated assay doesn't retroactively weaken the count. It gives field teams a sharper tool from here on. And those 754 deaths in the DRC as of July 15 are real, regardless of which test confirmed the cases. Fair. But the other piece arrived the same day — an international treatment trial. Cera, the outbreak's still described as expanding, and you're going to run randomization and consent protocols in the middle of that? How do you enroll people in a clinical trial in the middle of a fire? Carefully. It's been done before, and trial design can adapt to an emergency. For listeners, here's the honest interim: right now, there's no licensed treatment proven for this specific virus. The trial is the path to one. It doesn't mean one exists yet. And that's the arc for me this week. We started with 'deploy what we have.' We're ending with WHO building the test and the treatment mid-outbreak, in real time, while it spreads. In one breath, they're admitting the gap and laying out a plan. It is. And look at Uganda: 20 cases, two deaths, unchanged since June 21. That stability is the quiet good news underneath a loud, hard week. So when responders show up to a Bundibugyo outbreak, how do they know whether the Ebola tools they already have — vaccines, treatments, tests — will actually work on a different virus species? They don't know for certain yet, and that's the core problem. Bundibugyo virus is related to the more familiar Zaire ebolavirus, but it's a distinct species, first identified in Uganda in 2007. The licensed tools were developed and tested against Zaire, not Bundibugyo. Take Ervebo: it's licensed specifically for Ebola virus disease caused by Zaire ebolavirus. Under WHO's emergency guidance issued in May, any cross-protection against Bundibugyo is still an open question, and officials have to weigh whatever limited evidence is available. Treatments are on a separate track. Clinical trials to establish a standard of care for the Bundibugyo strain only began on July 2nd at the Evangelical Medical Center in Bunia, in Ituri province, the outbreak's epicenter. The lead researcher, Dr. Placide Mbala of the DRC's National Institute of Biomedical Research, said results could take three to six months, depending on how the outbreak evolves. In the meantime, a research perspective published in npj Viruses says there's a genuine lack of licensed countermeasures for this virus. Responders are relying on basic infection prevention and control, case isolation, and supportive care rather than proven targeted therapies. So the trials could wrap up in as little as three months. But what if the outbreak is already winding down by then, and there aren't enough patients enrolled to produce solid data? That's the bind in outbreak science: the same conditions that make a trial urgent can also make it hard to finish. What to watch is whether WHO's emergency framework yields enough evidence on Ervebo's potential cross-protection to support broader vaccine deployment before the treatment results arrive. Otherwise, the vaccine and treatment tracks may simply stay open in parallel. Dr. Mbala's three-to-six-month timeline puts the earliest findings in the fall. So the way cases move in Ituri over the next few weeks could determine whether the trial gathers enough evidence at all. Have feedback, a story idea, or a correction? Email us at ebolawatch at lantern podcasts dot com. We’d be glad to hear from you.
One thing we’re watching: WHO’s Bundibugyo treatment trial is expected to take three to six months to produce results, depending on how the outbreak evolves.
You’ll find links to every story in today’s show notes if you’d like to read further.
That’s Ebola Watch for today. This is a Lantern Podcast.